All News
Filter News
Found 629 articles
-
Rigel Pharmaceuticals, Inc. Release: Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL; Results to be Presented at Lymphoma Meeting in Lugano, Switzerland
6/3/2008
-
Rigel Pharmaceuticals, Inc. to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
6/3/2008
-
VentiRx Pharmaceuticals, Inc. Appoints Dr. Elliott Grossbard to Board of Directors; Rigel Pharmaceuticals, Inc. CMO to Add Valuable Clinical Development Expertise
5/22/2008
-
Rigel Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
5/7/2008
-
Rigel Pharmaceuticals, Inc.'s R788 Slows Progression of Murine Lupus in Preclinical Studies
4/29/2008
-
Rigel Pharmaceuticals, Inc.'s R788 Shows Preclinical Activity in Type 1 Diabetes Model
4/8/2008
-
Daniel Magilavy, M.D. Joins Rigel Pharmaceuticals, Inc. as Vice President of Clinical Research
2/26/2008
-
Rigel Pharmaceuticals, Inc. Announces Fourth Quarter and Year End 2007 Financial Results
2/12/2008
-
Rigel Pharmaceuticals, Inc. to Present at Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/6/2008
-
Rigel Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
2/1/2008
-
Rigel Pharmaceuticals, Inc. Announces Offering of 4,000,000 Shares of Common Stock
1/25/2008
-
Rigel Pharmaceuticals, Inc. to Present Programs at Four Upcoming Scientific Conferences
1/15/2008
-
Rigel Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
1/9/2008
-
Rigel Pharmaceuticals, Inc.'s R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study Achieves Statistically Significant ACR20, ACR50 & ACR70 Results
12/13/2007
-
Rigel Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer Inc.
12/6/2007
-
Rigel Pharmaceuticals, Inc. Announces Presentations at the 2007 American Society of Hematology Meeting
12/5/2007
-
Rigel Pharmaceuticals, Inc. to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
11/26/2007
-
Merck Serono Exercises Option to Rigel Pharmaceuticals, Inc.'s R763/AS703569 and Aurora Kinase Inhibitors in the Japanese Territory
11/14/2007
-
Rigel Pharmaceuticals, Inc. R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
11/9/2007
-
Rigel Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
11/6/2007